Exchange: NYSE Sector: Healthcare Industry: Drug Manufacturers—General
-0.15% $20.37
America/New_York / 8 mai 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 5 238.57 mill |
EPS: | 4.08 |
P/E: | 4.99 |
Earnings Date: | Aug 06, 2024 |
SharesOutstanding: | 257.17 mill |
Avg Daily Volume: | 2.40 mill |
RATING 2024-05-08 |
---|
S- |
Strong Buy |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Buy | |
Return On Equity: | Strong Buy | |
Return On Asset: | Buy | |
DE: | Strong Buy | |
P/E: | Neutral | |
Price To Book: | Strong Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
4/22 | 1/23 | 2/23 | 3/23 | 4/23 | 1/24 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.32x |
Company: PE 4.99 | sector: PE 15.43 |
PE RATIO: COMPANY / INDUSTRY |
---|
0.21x |
Company: PE 4.99 | industry: PE 24.13 |
DISCOUNTED CASH FLOW VALUE |
---|
$37.87 (85.92%) $17.50 |
Date: 2024-05-09 |
Expected Trading Range (DAY) |
---|
$ 19.87 - 20.88 ( +/- 2.48%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-05-04 | Morrissey Joseph T. Jr. | Buy | 3 604 | Common Stock |
2024-05-04 | Morrissey Joseph T. Jr. | Sell | 1 568 | Common Stock |
2024-05-04 | Morrissey Joseph T. Jr. | Sell | 3 604 | Restricted Stock Units |
2024-05-04 | Nisita Vittorio | Buy | 2 078 | Common Stock |
2024-05-04 | Nisita Vittorio | Sell | 712 | Common Stock |
INSIDER POWER |
---|
71.83 |
Last 100 transactions |
Buy: 1 855 517 | Sell: 300 367 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $20.37 (-0.15% ) |
Volume | 1.983 mill |
Avg. Vol. | 2.40 mill |
% of Avg. Vol | 82.56 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology products, including Ontruzant and Aybintio. It also offers cardiovascular products, consisting of several cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for various treatments to control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. In addition, the company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. The company sells its products primarily to drug wholesalers and retailers, hospitals, and government agencies, as well as managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was incorporated in 2020 and is based in Jersey City, New Jersey.